Estimates of Opioid Use Disorder and Treatment Needs in California

California Totals, March 19, 2018

- In 2016, an estimated 5.8 percent of people ages 12 years and older (1,934,253 people) misused opioids in California, and 1.1 percent of people (348,193 people) had an opioid use disorder (OUD), defined as opioid abuse or dependence. Approximately one-fifth of those who misuse opioids have an OUD.
- California had 2,186 opioid overdose deaths in 2016.
- There are 165,977 to 245,093 people with OUD in California without local access to opioid agonist treatment (i.e. buprenorphine or methadone). Since there are no regulatory barriers to naltrexone and counseling treatments, this snapshot focuses on agonists.

Percent of the Population 12 Years and Older with Opioid Use Disorder (Abuse or Dependence) in California

<table>
<thead>
<tr>
<th>Measure</th>
<th>Count and Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>All opioid overdose deaths, 2016</td>
<td>2,186 deaths; 4.9 per 100,000 people</td>
</tr>
<tr>
<td>Buprenorphine prescriptions, 2016</td>
<td>624,947 prescriptions; 13.5 per 1,000 people</td>
</tr>
<tr>
<td>Methadone patients at OTPs, 2016</td>
<td>37,134 methadone patients at OTPs; 112.1 per 100,000 people</td>
</tr>
<tr>
<td>Buprenorphine-waivered prescribers, February 2018 estimate</td>
<td>3831 prescribers with a 30-patient limit, 743 prescribers with a 100-patient limit, 175 prescribers with a 275-patient limit.</td>
</tr>
<tr>
<td>Estimated count and rate of opioid misuse</td>
<td>1,934,253 people misused opioids; 5.8 per 100 people</td>
</tr>
<tr>
<td>Estimated count and rate of OUD</td>
<td>348,193 people with OUD; 1.1 per 100 people</td>
</tr>
<tr>
<td>Estimated number of people with OUD who could be treated, given current buprenorphine and methadone treatment capacity</td>
<td>Between 103,505 and 191,142 people could be treated given current capacity, depending on how many patients each buprenorphine prescriber treats.</td>
</tr>
<tr>
<td>Estimated treatment gap, assuming all people with OUD seek treatment</td>
<td>Between 165,977 and 245,093 people with OUD do not have access to treatment, based on current opioid agonist treatment capacity.</td>
</tr>
<tr>
<td>Count and percent of prescribers with a buprenorphine waiver</td>
<td>There are 198,045 prescribers in California, and 2.4% have a buprenorphine waiver.</td>
</tr>
</tbody>
</table>

Strategies to Meet Demand for Treatment

Increase prescribers: Adding at least 4,199 prescribers with a 30-patient limit would fill 15.1% of the treatment gap, if all prescribers treat an average of 9 patients each. Adding at least 3,525 prescribers with a 30-patient limit would fill 31.9% of the treatment gap, if new prescribers treat an average of 15 patients and current prescribers treat half of their maximum waiver capacity.

Increase resources: Work with health plans for prescriber outreach; add MAT in health centers, jails, EDs, hospitals, maternity practices, and existing addiction treatment programs; market MAT telehealth to the public; work with opioid treatment programs to add med units and spokes; work with county Alcohol and Drug departments to coordinate counseling and other services; expand MAT services through the Drug Medi-Cal waiver; engage with local opioid safety coalition.
Data sources and notes:

- Opioid misuse is defined as self-reported use of heroin or misuse of prescription pain relievers. OUD is defined as self-report of heroin use or criteria for opioid abuse or dependence consistent with Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- Each dot in this chart shows the estimated rate of OUD among those 12 years and older in each county. The featured county’s rate is shown as a blue dot; other California county rates are shown as dots. The box in the boxplot has a middle line that shows the median rate across counties. The ends of the box show the rate at the lowest/highest quarter of counties.
- California Opioid Overdose Surveillance Dashboard. Buprenorphine prescriptions are by patient location and exclude Butrans.
- Estimates based on DEA Active Controlled Substances Act (CSA) Registrants database and Controlled Substance Utilization Review and Evaluation System (CURES) data as well as several data sources; see methods below and the appendix methodology.
- Estimates based on DEA CSA Registrants database and a range of estimated patients per prescriber; see appendix. Treatment capacity and treatment gap estimates are rounded up to the nearest integer.
- Estimates based on OUD prevalence estimates, DEA CSA Registrants database, and a range of estimated patients per prescriber; see appendix. Prescriber estimates are rounded up to the nearest integer. The treatment gap could also be addressed by encouraging currently waivered prescribers to increase the number of patients treated and/or increasing their waiver limit.

Summary of Methods

This fact sheet presents data from the California Opioid Overdose Surveillance Dashboard and other data sources, as well as county-level estimates based on new analyses by researchers at the Urban Institute (www.urban.org). To estimate the demand for treatment, we calculated county rates of OUD, starting with estimates of past-year nonmedical use of prescription pain relievers for 26 substate regions in California from the NSDUH (Lipari et al. 2017), and adjusting these estimates for additional NSDUH estimates of heroin use disorder and recent trends. We then used regression models to predict county-level rates as a function of explanatory variables that have an empirical relationship with OUD (Alzeer et al. 2017; Paulozzi et al. 2017). We tested a variety of models that produced similar patterns of results. We applied county-level estimates of the population from the Centers for Disease Control and Prevention (CDC) to create county-level counts, which were adjusted to match the NSDUH substate counts. To estimate county OUD rates, the share of OUD among those who misuse opioids (0.2 based on 2016 national NSDUH estimates) was applied to estimated opioid misuse rates. To estimate buprenorphine MAT capacity, we drew on the DEA Active Controlled Substances Act (CSA) Registrants database, which includes all DATA-waived buprenorphine prescribers. We mapped prescriber addresses to county using a ZIP code to county crosswalk from UDS Mapper and the Census Bureau, and for ZIP codes that map to more than one county, we geocoded addresses through the Google Geocoding API. In counties where the number of prescribers from California’s CURES data was larger than our estimate based on DEA data, we adjusted the estimated number of waivered prescribers, preserving the distribution of waiver limits from the DEA data. We calculated county buprenorphine treatment capacity using a lower bound of estimated average capacity in California of nine patients per provider (Thomas et al. 2017) and an upper bound equal to half of a prescriber’s estimated maximum patient waiver limit. Treatment capacity related to out-of-county buprenorphine prescribers and methadone slots at OTPs in the county were added. To compute the treatment gap, i.e. the number of individuals with OUD who do not have access to MAT in their county, we assumed that all individuals with OUD are likely to seek MAT. We calculated the treatment gap by subtracting the low and high estimated range of the treatment capacity in each county from the estimated number with OUD. We computed the estimated number of additional 30-waivered buprenorphine prescribers needed per county to achieve capacity to fill the estimated treatment gap. We present strategies to meet demand for treatment, showing a range using lower and upper estimates of the treatment gap and the treatment capacity. In cases where the number of new prescribers needed would be more than double the number of current buprenorphine prescribers, we present an alternative, more feasible strategy of doubling the number of prescribers. In these cases, we present the percent of the treatment gap that would be filled.

For more information on the methods used in producing these estimates, see the methodological appendix at: www.urban.org/research/publication/county-level-estimates-opioid-use-disorder-and-treatment-needs-california.

About the Authors Lisa Clemans-Cope is a senior health economist and Marni Epstein is a research assistant in the Urban Institute’s Health Policy Center. Doug Wissoker is a senior fellow in the Urban Institute’s Statistical Methods Group. Contact: Lisa Clemans-Cope at iclemans@urban.org.

Suggested Citation: Lisa Clemans-Cope, Marni Epstein, and Doug Wissoker. County-Level Estimates of Opioid Use Disorder and Treatment Needs in California. The Urban Institute. March 19, 2018.